TP53, widely known as the “guardian of the genome,” plays a critical tumor-suppressive role. However, mutations in TP53 not only impair cancer cell-intrinsic functions but also exert profound non-cell-autonomous effects—particularly on the immune system. This new research highlights how mutant p53 profoundly remodels the TIME by influencing the differentiation trajectory and functionality of infiltrating CD8+ T cells, key players in anti-tumor immunity.

Employing cutting-edge single-cell transcriptomics and immunophenotyping, the study characterized the exhaustion phenotype dominated by TP53-mutant-driven CD8+ T cell populations in urothelial cancer patients. These exhausted cells exhibited hallmarks of dysfunction, including overexpression of inhibitory receptors and impaired effector functions, which collectively contribute to immune evasion by the tumor.

Crucially, this dysfunctional immune state correlates with a lethal clinical trajectory and markedly reduced responsiveness to immunotherapies such as immune checkpoint blockade, which rely on reactivating exhausted T cells. The study suggests that TP53 mutations bias the immune response toward a suppressed and ineffective anti-tumor attack, thereby fostering therapeutic resistance.

The implications extend beyond prognostic value. By demonstrating that TP53 mutation status directly influences the immune milieu and T cell exhaustion, the research paves the way for tailored therapeutic strategies. Targeting the pathways linking mutant p53 to immune dysfunction could potentially restore effective CD8+ T cell activity and enhance responsiveness to existing immunotherapies.

Further mechanistic insights revealed that mutant p53 may alter cytokine profiles and antigen presentation within the tumor, thereby orchestrating an immunosuppressive environment advantageous to tumor survival. This intricate cross-talk between tumor genetics and immune modulation calls for an integrated therapeutic approach combining genomic and immune checkpoint profiling.

This study underscores the necessity of considering the tumor’s genetic landscape when addressing immune dysfunction in cancer. It positions TP53 mutation not only as a biomarker of poor prognosis but also as a driver of immune escape mechanisms that limit treatment success.

Going forward, therapeutics designed to counteract p53 mutation-induced immune exhaustion or reprogram the TIME may revolutionize the management of aggressive urothelial carcinoma, offering renewed hope for patients historically facing dismal outcomes.

Subject of Research: TP53 mutations and their impact on CD8+ T cell exhaustion and immunotherapy resistance in urothelial carcinoma.

Article Title: TP53 mutation-biased CD8+ T cell exhaustion drives lethal outcome and therapy resistance in urothelial carcinoma.

Article References:
Su, X., Jin, K., Zeng, H. et al. TP53 mutation-biased CD8+ T cell exhaustion drives lethal outcome and therapy resistance in urothelial carcinoma. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03548-1

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03548-1

CAR T cells represent a revolutionary approach in oncology, effectively turning a patient’s immune system into a tailored weapon against cancer. By genetically modifying T cells to express chimeric antigen receptors (CARs), researchers have enabled these immune cells to target and destroy malignant cells selectively. This technique has shown extraordinary success in curing patients suffering from previously untreatable blood cancers, such as specific types of leukemia and lymphomas. However, the broad application of this therapy remains challenging due to the fact that many patients do not respond favorably. This shortcoming is often attributable to the intrinsic limitations of T cells, which can diminish their effectiveness in the hostile tumor microenvironment.

The new study spearheaded by Paul Datlinger and his colleagues at CeMM has led to the creation of a transformative platform known as CELLFIE—short for CAR T cell engineering and high-content CRISPR screening technology. This comprehensive approach permits the systematic modification of CAR T cells at the genetic level, enabling researchers to screen for gene knockouts that improve the functionality and persistence of these therapeutic cells. Utilizing cutting-edge CRISPR technology, the researchers were able to test the impact of knocking out various human genes on CAR T cell performance, providing them with invaluable insights into genetic factors that enhance tumor-fighting abilities.

One of the most remarkable findings from this research was the identification of the RHOG gene as a critical target for increasing the potency of CAR T cells. Through systematic screening, the team discovered that the knockout of the RHOG gene led to a marked enhancement in the T cells’ abilities to combat leukemia in preclinical models. This insight underscores the complexity of CAR T cell functionality; while these cells have been engineered to perform a specific task, certain genetic factors that may bolster a natural immune response can paradoxically undermine their effectiveness in engineered forms, highlighting the nuanced interplay of genetics in immune response.

Eugenia Pankevich, a co-first author on the paper, elaborates on the significance of their findings. The researchers have demonstrated that certain genes, while crucial for natural immune functions, can hinder the effectiveness of CAR T therapies. By utilizing CRISPR technology to eliminate these counterproductive genetic components, the research team was able to enhance the overall therapeutic potential of CAR T cells significantly. This novel application of gene editing provides an exciting avenue for creating more effective cancer treatments that could drastically alter the prognosis for many patients.

In their pursuit of advancing CAR T cell therapy, the researchers employed their CELLFIE platform to evaluate the effects of thousands of gene knockouts comprehensively. In particular, they sought to identify genetic modifications that would allow the engineered T cells to persist longer in the body, resist exhaustion, and enhance their proliferative capacity when faced with tumor cells. The research incorporated an innovative in vivo CRISPR screening approach, corroborating the beneficial effects of specific genetic modifications in real-time within preclinical mouse models, a promising strategy that could streamline future clinical applications.

The discovery did not stop with the RHOG knockout. The team found that combining knockouts of RHOG with another gene known as FAS resulted in synergistic effects that significantly improved the therapeutic profile of CAR T cells. By knocking out both genes, the engineered cells demonstrated faster proliferation rates, increased activity levels, and a markedly greater ability to cure aggressive leukemia in murine models. This revelation opens up exciting possibilities for combinatorial genetic modifications in CAR T cell therapy, suggesting that a multi-target approach could enhance treatment outcomes even further.

Beyond immediate applications in blood cancers, the CELLFIE platform promises broader implications for immunotherapy. The technology presents a customizable framework capable of integrating genome-wide screenings and optimization protocols that aim to tailor immune therapies for a range of cancers, including traditionally harder-to-treat solid tumors. The potential to adapt these precision therapies further to address autoimmune disorders and regenerative medicine challenges presents a compelling opportunity for optimizing patient care based on individual genetic and immune profiles.

Christoph Bock, the principal investigator in the study, articulates the long-term vision for this research. By establishing a robust methodology for systematically enhancing cell-based immunotherapies, scientists are poised to pave the way for the next generation of immune therapies. As researchers delve deeper into understanding the programming of T cells as effective anti-cancer agents, the future of medicine may lie in these ‘living drugs’ that possess the ability to adapt and respond dynamically to various diseases.

The implications of this study are profound, particularly as clinical validation processes begin. The researchers are optimistic about undertaking clinical trials to assess the monumental potential of RHOG and FAS knockout CAR T cells in human subjects suffering from various forms of cancer. In particular, the promising synergy observed with dual gene knockouts could herald a new era of more effective treatments that incorporate multiple genetic targets.

As CAR T cell therapy continues to revolutionize cancer treatment landscapes, the prospects of enhancing efficacy through innovative genetic strategies like those outlined in this study may ultimately lead to broader applications and increased access for patients. With the introduction of CELLFIE and the promise of genetic modifications to enhance the power and persistence of CAR T cells, the boundaries of what is possible in cancer immunotherapy are expanding. This research not only enhances our understanding of the complexities of immune system dynamics but also represents a significant leap forward in the efficacy of personalized medicine.

As this field gains momentum, it is imperative for the scientific community to continue exploring these pathways. The evolution of CAR T cells into more effective therapies not only has the potential to save countless lives but also paves the way for re-imagining our approach to battling a wider spectrum of diseases. The intersection of genetics and immune therapy is rapidly evolving, with research like that conducted by the CeMM leading the charge towards a brighter future in oncology and beyond.

As the world eagerly awaits further developments in this exciting field, the researchers at CeMM and the Medical University of Vienna stand at the forefront of a transformative journey aimed at reshaping cancer treatment and improving patient outcomes through meticulous scientific exploration and innovation.

Subject of Research: Cells
Article Title: Systematic discovery of CRISPR-boosted CAR T cell immunotherapies
News Publication Date: 24-Sep-2025
Web References: Nature Journal
References:
Image Credits: © Arc Institute; Wolfgang Däuble/CeMM

Keywords

EBV is a ubiquitous herpesvirus known for establishing latent infections in B cells. While typically controlled by the immune system, in certain contexts—such as in EBV+ DLBCL—it contributes to oncogenesis and tumor progression. The ability of the virus to dampen anti-tumor immunity, particularly by modulating T cell function, is thought to be central to this process. To dissect this immune dysfunction, researchers embarked on a comprehensive investigation comparing immune profiles among patients with EBV+ DLBCL, EBV-negative DLBCL (EBV− DLBCL), and healthy controls.

One of the core findings from this study was the remarkable decrease in interferon-gamma (IFN-γ) secreting T cells following stimulation with EBV-derived peptides in EBV+ DLBCL patients compared to their EBV-negative counterparts. IFN-γ is a critical cytokine in antitumor immunity, orchestrating the activation of cytotoxic T cells and natural killer cells. The diminished IFN-γ response signals an impaired antiviral and antitumor T cell response, laying the foundation for viral persistence and lymphoma progression.

Delving deeper, flow cytometric analysis revealed significant alterations in the composition of T cell subsets in EBV+ patients. There was a marked reduction in total lymphocyte counts, with notable depletion of both CD8+ cytotoxic T lymphocytes and CD4+ helper T cells exhibiting central memory phenotypes. Central memory T cells are critical for long-lived immune memory and rapid recall responses; their diminishment suggests a compromised capacity to mount effective immune defenses upon antigen re-exposure.

Simultaneously, the study observed an increase in effector memory T cells within both CD4+ and CD8+ compartments. While effector memory T cells provide more immediate responses, their accumulation in chronic viral infections or cancer can reflect a skewed differentiation state, often accompanied by functional exhaustion. In the EBV+ lymphoma context, this shift hints at a chronic antigenic stimulation driving T cells towards a dysfunctional profile.

The hallmark of T cell exhaustion—characterized by upregulated inhibitory receptors—was strikingly evidenced in these patients. Elevated expression of Programmed cell death protein 1 (PD-1) on both CD4+ and CD8+ T cells was documented, signifying an exhausted immunophenotype. PD-1 is a co-inhibitory receptor that, when overexpressed, dampens T cell activation and effector function, enabling tumors and viruses to evade immune surveillance. This finding underscores why EBV+ DLBCL patients might not adequately control viral oncogenesis.

Furthermore, the research illuminated a reduction in the subpopulation of CD4+ T cells lacking both TIM-3 and CTLA-4 expression. These molecules are additional immune checkpoints associated with exhaustion and immune regulation, and their altered expression patterns further map the dysfunctional immune landscape in EBV+ lymphomas.

Senescence markers were also evaluated in T cell subsets, revealing a significant decline in CD28+KLRG1− and CD28+CD57−KLRG1− subsets among CD8+ T cells in EBV+ patients. The loss of CD28, a vital costimulatory molecule for T cell activation, alongside the upregulation of senescence-associated markers like KLRG1 and CD57, indicates an aged or terminally differentiated state of T cells. This senescent phenotype impairs proliferation and cytokine production, compounding the functional deficits observed.

Strikingly, when peripheral blood mononuclear cells were stimulated with PMA and brefeldin A to assess intrinsic IFN-γ production independent of antigen stimulation, CD8+ T cells from EBV+ patients still demonstrated reduced IFN-γ expression. This suggests an intrinsic impairment within cytotoxic T cells, beyond mere antigen-specific exhaustion, indicative of a pervasive immune dysfunction.

Taken together, these comprehensive immunophenotypic and functional analyses illuminate a compromised cellular immune milieu in EBV+ DLBCL patients. The skewing of T cell subsets away from naïve and central memory phenotypes towards exhausted, senescent, and dysfunctional states manifests as an impaired capacity to respond effectively to EBV antigens. This deficit likely contributes to viral persistence and unchecked tumor growth, underscoring the critical link between EBV-driven immune dysregulation and lymphoma pathogenesis.

Clinically, these findings have profound implications. They suggest that traditional therapeutic approaches targeting the tumor alone may be insufficient. Instead, revitalizing T cell function through checkpoint blockade therapies—for instance, anti-PD-1 or anti-CTLA-4 antibodies—could restore immune competence against EBV and improve patient outcomes. However, the presence of senescent T cells implies that combinatorial strategies addressing both exhaustion and senescence might be necessary.

Moreover, the reduction in critical co-stimulatory molecules such as CD28 in CD8+ populations indicates a potential challenge for adoptive T cell therapies or vaccines relying on these cells. Understanding the exact molecular mechanisms behind this loss could guide the engineering of more resilient T cell products capable of overcoming these inhibitory environments.

This study also provides a valuable framework for investigating other EBV-associated malignancies, such as nasopharyngeal carcinoma or Hodgkin lymphoma, where similar immune evasion mechanisms might be at play. Broadly, mapping the immune landscape with such granularity empowers the design of precision immunotherapies tailored to the unique immune contexts created by oncogenic viruses.

Furthermore, these insights into T cell dysfunction might inform diagnostic strategies, where immune profiling could serve as a biomarker to predict disease prognosis or to monitor therapeutic response. For patients with EBV+ DLBCL, tracking changes in T cell exhaustion and senescence markers could guide individualized treatment decisions.

From an immunological perspective, the study reaffirms the intricate balance between immune activation and regulation. Chronic viral infections like EBV exert ongoing antigenic pressure, driving T cells into states of exhaustion and senescence, which tumors exploit to evade clearance. Disrupting this balance restores immune surveillance but requires nuanced approaches that prevent hyperactivation and autoimmunity.

In conclusion, the dysfunction of peripheral EBV antigen-specific T cells in EBV+ diffuse large B-cell lymphoma represents a pivotal obstacle to effective immune responses against this formidable cancer. By elucidating the phenotypic and functional impairments—ranging from altered T cell subset distribution to elevated exhaustion and senescence markers—this research paves the way for novel therapeutic strategies aimed at reinvigorating the immune system. The fight against EBV-associated lymphomas may well hinge on overcoming these immunological barriers, transforming a dysfunctional foe into a powerful ally in cancer control.

Subject of Research: Dysfunction of peripheral EBV antigen-specific T cells in Epstein–Barr virus positive diffuse large B-cell lymphoma

Article Title: Peripheral EBV antigen-specific T cell is dysfunctional in Epstein–Barr virus positive diffuse large B-cell lymphoma

Article References:
Gao, L., Wang, L., Xue, C. et al. Peripheral EBV antigen-specific T cell is dysfunctional in Epstein–Barr virus positive diffuse large B-cell lymphoma. BMC Cancer 25, 1318 (2025). https://doi.org/10.1186/s12885-025-14723-7

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14723-7